BURLINGTON, Vermont – June 25, 2024 – The International Academy on the Science and Impact of Cannabis (IASIC) released its official statement against the proposed rescheduling of Cannabis from Schedule I to Schedule III of the Controlled Substances Act:
As physicians and concerned citizens of the United States of America, the International Academy on the Science and Impact of Cannabis believes that re-scheduling will have immediate and irreparable harm to the public health and vehemently oppose the removal of cannabis from Schedule 1. Specific objections include (1) The Department of Health and Human Services (HHS) inappropriately changed the definition of currently acceptable medical use (CAMU); (2) Even under the new definition, cannabis still does not meet the requirements for CAMU; (3) Proper regulation of cannabis as a schedule 3 drug cannot be achieved while non-medical cannabis commerce is allowed.
“HHS and those who are pushing rescheduling of cannabis are unaware or ignoring the huge amount of science on the medical harms of cannabis. There is zero benefit and only problems to be had from rescheduling,” said Eric A. Voth, MD, FACP, President and Chairman of the Board, The International Academy on the Science and Impact of Cannabis.
An official request for a hearing with the DEA has been submitted by IASIC during the current open comment period, with its leadership urging the presentation of medical and scientific research from its physician-driven organization of international experts on cannabis.
IASIC has provided substantial education and background on the impending harm of the proposed rescheduling in its monthly speaker series on June 11th as well as on the High Truths on Drugs and Addiction podcast with episode #182: High Truths on Drugs and Addiction on Rescheduling of Marijuana with IASIC.
Adolescents who used e-cigarettes were significantly more likely to become new smokers of cannabis shortly thereafter, a cohort study found. Cannabis-naive adolescents reporting ever vaping at baseline were more than twice as likely to report also using cannabis when surveyed a year later (adjusted RR 2.57 vs nonusers of e-cigarettes, 95% CI 2.04-3.09), reported Ruoyan
Cannabis withdrawal is a well-characterized phenomenon that occurs in approximately half of regular and dependent cannabis users after abrupt cessation or significant reductions in cannabis products that contain Δ9-tetrahydrocannabinol (THC). This review describes the diagnosis, prevalence, course and management of cannabis withdrawal and highlights opportunities for future clinical research. Read the full study published in
Higher concentrations of tetrahydrocannabinol or THC — the part of the marijuana plant that makes you high — are causing more people to become addicted in many parts of the world, a new review of studies found. Read the full article from CNN here: https://amp.cnn.com/cnn/2022/07/25/health/marijuana-potency-addiction-study-wellness/index.html For more information on the International Academy on the Science
Regardless of the type of substance-dependent addiction — whether alcohol, opiates, nicotine, or cannabinoids — the brain pathway is the same: the dopamine system. This system is also responsible for curiosity, desire, learning, and actions. Various substances lead to increased neurotransmitter release. The endocannabinoid system acts as a damper on this system. System stabilization is
To the Editor On behalf of our coauthors, we write to respond to concerns raised about the methods and analyses for the Research Letter, “Association of Marijuana Legalization With Marijuana Use Among US High School Students, 1993-2019,” published in JAMA Network Open on September 7, 2021.1 These concerns were brought to our attention by readers
Jodie Sharp’s days were all broken up the same way. “I smoked to go to work, smoked to do the washing-up, smoked for chill time.” Smoking marijuana “was a totally regular habit and every time I did it, I was smoking in exactly the same way, getting the same experience all over again.” Sharp used
Obtaining a medical marijuana card may pose a risk for those who use cannabis products to treat pain, anxiety, or depression, according to a Massachusetts General Hospital study. In a significant minority of individuals, researchers found those at greatest risk of developing the addictive symptoms of cannabis use disorder (CUD) were seeking relief from anxiety
Cannabis use disorder (CUD) is the most common non-alcohol related substance use disorder (SUD) in the United States and is especially prevalent among returning veterans. The long-term mental health correlates of CUD remain unknown, which is significant given the rise in legalization and also recreational and medicinal cannabis use nationally. You can access the full
Over the last two decades there has been considerable movement at the state-level to legalize marijuana, initially for medical purposes and more recently for recreational consumption. Despite prior research, it is unclear how, if at all, these policies are related to rates of opioid-involved overdose deaths, which have trended rapidly upwards over time and represent
Listen to Joe Eberstein’s discussion on High Truths on Drugs and Addiction, Episode #5 A high school student asks “Isn’t it safer to use marijuana over alcohol?” Joe Eberstein is an IASIC advisor, prevention specialist, motivational speaker and expert on youth marijuana use and vaping. Should parents be honest with their prior drug use with kids? How
The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,
Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of
Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when
The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,
